Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Neutral antagonism at the cannabinoid 1 receptor: a safer treatment for obesity
Frank J. Meye, Viviana Trezza, Louk J. M. J. Vanderschuren, et al.
Molecular Psychiatry (2012) Vol. 18, Iss. 12, pp. 1294-1301
Open Access | Times Cited: 76

Showing 26-50 of 76 citing articles:

The vital role of constitutive GPCR activity in the mesolimbic dopamine system
Frank J. Meye, Geert M. J. Ramakers, Roger A.H. Adan
Translational Psychiatry (2014) Vol. 4, Iss. 2, pp. e361-e361
Open Access | Times Cited: 47
Endocannabinoid signaling in hypothalamic circuits regulates arousal from general anesthesia in mice
Haixing Zhong, Tong Li, Ning Gu, et al.
Journal of Clinical Investigation (2017) Vol. 127, Iss. 6, pp. 2295-2309
Open Access | Times Cited: 47
Possible Therapeutic Doses of Cannabinoid Type 1 Receptor Antagonist Reverses Key Alterations in Fragile X Syndrome Mouse Model
María Gomis-González, Arnau Busquets‐Garcia, Carlos Matute, et al.
Genes (2016) Vol. 7, Iss. 9, pp. 56-56
Open Access | Times Cited: 46
Metabolic side effects induced by olanzapine treatment are neutralized by CB1 receptor antagonist compounds co-administration in female rats
Paolo Lazzari, Valeria Serra, S. Marcello, et al.
European Neuropsychopharmacology (2017) Vol. 27, Iss. 7, pp. 667-678
Closed Access | Times Cited: 41
Cannabinoid Discrimination and Antagonism by CB1Neutral and Inverse Agonist Antagonists
Brian D. Kangas, Marcus S. Delatte, Kiran Vemuri, et al.
Journal of Pharmacology and Experimental Therapeutics (2013) Vol. 344, Iss. 3, pp. 561-567
Open Access | Times Cited: 43
The CB1 Neutral Antagonist Tetrahydrocannabivarin Reduces Default Mode Network and Increases Executive Control Network Resting State Functional Connectivity in Healthy Volunteers
Ewelina Rzepa, Luke Tudge, Ciara McCabe
The International Journal of Neuropsychopharmacology (2015) Vol. 19, Iss. 2, pp. pyv092-pyv092
Open Access | Times Cited: 40
Endocannabinoids and striatal function
Fabrício A. Moreira, Bianca Jupp, David Belin, et al.
Behavioural Pharmacology (2014) Vol. 26, Iss. 1 and 2 - Special Issue, pp. 59-72
Open Access | Times Cited: 38
mGluR-LTD at Excitatory and Inhibitory Synapses in the Lateral Habenula Tunes Neuronal Output
Kristina Valentinova, Manuel Mameli
Cell Reports (2016) Vol. 16, Iss. 9, pp. 2298-2307
Open Access | Times Cited: 38
Dissociating the role of endocannabinoids in the pleasurable and motivational properties of social play behaviour in rats
E. J. Marijke Achterberg, Maaike M.H. van Swieten, Nina V. Driel, et al.
Pharmacological Research (2016) Vol. 110, pp. 151-158
Open Access | Times Cited: 34
Preclinical Studies of Cannabinoid Reward, Treatments for Cannabis Use Disorder, and Addiction-Related Effects of Cannabinoid Exposure
Leigh V. Panlilio, Zuzana Justinová
Neuropsychopharmacology (2017) Vol. 43, Iss. 1, pp. 116-141
Open Access | Times Cited: 34
Understanding the possible role of endocannabinoid system in obesity
Tapan Behl, Swati Chadha, Monika Sachdeva, et al.
Prostaglandins & Other Lipid Mediators (2020) Vol. 152, pp. 106520-106520
Closed Access | Times Cited: 28
Comparing adenosine A2A receptor modulation of cannabinoid CB1 receptor‐mediated inhibition of GABA and glutamate release in rodent striatal nerve terminals
Samira G. Ferreira, Rafael Mariano de Bitencourt, Pedro Garção, et al.
European Journal of Neuroscience (2025) Vol. 61, Iss. 1
Closed Access
Circulating endocannabinoids and brain anatomy: unraveling the weight loss connection through lifestyle and surgery approaches
Gabrielle St-Arnaud, Tristan Rocheleau, Alain Veilleux, et al.
(2025)
Closed Access
CNS-targeting pharmacological interventions for the metabolic syndrome
Kerstin Stemmer, Timo D. Müller, Richard D. DiMarchi, et al.
Journal of Clinical Investigation (2019) Vol. 129, Iss. 10, pp. 4058-4071
Open Access | Times Cited: 27
Disruption of tonic endocannabinoid signalling triggers cellular, behavioural and neuroendocrine responses consistent with a stress response
Gavin N. Petrie, Georgia Balsevich, Tamás Füzesi, et al.
British Journal of Pharmacology (2023) Vol. 180, Iss. 24, pp. 3146-3159
Open Access | Times Cited: 9
Platelet integrin αIIbβ3 plays a key role in a venous thrombogenesis mouse model
Brian D. Adair, Conroy O. Field, José Luís Izquierdo Alonso, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 3
NESS06SM reduces body weight with an improved profile relative to SR141716A
Andrea Mastinu, Marilena Pira, Gérard A. Pinna, et al.
Pharmacological Research (2013) Vol. 74, pp. 94-108
Closed Access | Times Cited: 31
Biological evaluation of benzosuberones
Haider Behbehani, Kamal M. Dawood, Thoraya A. Farghaly
Expert Opinion on Therapeutic Patents (2017) Vol. 28, Iss. 1, pp. 5-29
Closed Access | Times Cited: 25
Identification of Novel CB2 Ligands through Virtual Screening and In Vitro Evaluation
Adam Stasiulewicz, Anna Leśniak, Magdalena Bujalska‐Zadrożny, et al.
Journal of Chemical Information and Modeling (2023) Vol. 63, Iss. 3, pp. 1012-1027
Open Access | Times Cited: 8
Targeting the interaction between fatty acid ethanolamides and nicotinic receptors: Therapeutic perspectives
Miriam Melis, Marco Pistis
Pharmacological Research (2014) Vol. 86, pp. 42-49
Closed Access | Times Cited: 23
Cannabinoid withdrawal in mice: inverse agonist vs neutral antagonist
Sherrica Tai, Spyros P. Nikas, Vidyanand G. Shukla, et al.
Psychopharmacology (2015) Vol. 232, Iss. 15, pp. 2751-2761
Open Access | Times Cited: 21
The Cannabinoid CB1 Antagonist TM38837 With Limited Penetrance to the Brain Shows Reduced Fear-Promoting Effects in Mice
Vincenzo Micale, Filippo Drago, Pia K. Noerregaard, et al.
Frontiers in Pharmacology (2019) Vol. 10
Open Access | Times Cited: 21
New perspectives on the role of the neurosteroid pregnenolone as an endogenous regulator of type‐1 cannabinoid receptor (CB1R) activity and function
Pierre‐Louis Raux, Guillaume Drutel, Jean‐Michel Revest, et al.
Journal of Neuroendocrinology (2021) Vol. 34, Iss. 2
Open Access | Times Cited: 18
Antihistaminergics and inverse agonism: Potential therapeutic applications
Federico Monczor, Natalia Fernández, Carlos P. Fitzsimons, et al.
European Journal of Pharmacology (2013) Vol. 715, Iss. 1-3, pp. 26-32
Open Access | Times Cited: 22
Brain endocannabinoid control of metabolic and non-metabolic feeding behaviors
Min Zhang, Qingyu Wang, Ying Wang
Neurochemistry International (2024) Vol. 183, pp. 105921-105921
Closed Access | Times Cited: 2

Scroll to top